Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 24Breast Neoplasms 15Carcinoma, Non-Small-Cell Lung 10Sarcoma 9Myelodysplastic Syndromes 9Stomach Neoplasms 8Multiple Myeloma 7Leukemia, Myelomonocytic, Chronic 7Myeloproliferative Disorders 6Uterine Cervical Neoplasms 5Lymphoma, Large B-Cell, Diffuse 5Lung Neoplasms 5Recurrence 4Prostatic Neoplasms 4Neoplasms 4Melanoma 4Leukemia, Monocytic, Acute 4Head and Neck Neoplasms 4Esophageal Squamous Cell Carcinoma 4Esophageal Neoplasms 4Carcinoma, Hepatocellular 4Biliary Tract Neoplasms 4Advanced Solid Tumour 4Stomatitis 3Squamous Cell Carcinoma of Head and Neck 3Ovarian Neoplasms 3Neuroendocrine Tumors 3Mucositis 3Leukemia, Myelomonocytic, Acute 3Cholangiocarcinoma 3

Interventions

PM 01183 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gastrointestinal Malignancies × Injections × Clear all
NCT05229588 2025-08-15

Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations

HonorHealth Research Institute

Phase 2 Completed
8 enrolled
Gastrointestinal

Gastrointestinal Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡